CAR-modified anti-CD19 T cells for the treatment of B-cell malignancies: Rules of the road

Expert Opinion on Biological Therapy

Volumn 14, Issue 1, 2014, Pages 37-49

  Gill, Saar ^a   Porter, David L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

B cell acute lymphoblastic leukemia; B cell lymphoma; CD19 redirected T cells; Chimeric antigen receptors

Indexed keywords

ANTI CD19 SCFV CD28 CD3ZETA; ANTINEOPLASTIC AGENT; BENDAMUSTINE; CD19 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; CHIMERIC PROTEIN; CYCLOPHOSPHAMIDE; ETANERCEPT; ETOPOSIDE; FLUDARABINE; GAMMA INTERFERON; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 7; IPILIMUMAB; LENTIVIRUS VECTOR; LYMPHOCYTE ANTIGEN RECEPTOR; PENTOSTATIN; RETROVIRUS VECTOR; RITUXIMAB; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; STEROID; T LYMPHOCYTE RECEPTOR; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADD ON THERAPY; ADOPTIVE TRANSFER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN PRESENTING CELL; B CELL LYMPHOMA; BACTEREMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CAPILLARY LEAK SYNDROME; CELL EXPANSION; CELL KILLING; CELL PROLIFERATION; CELL SURFACE; CEREBROVASCULAR ACCIDENT; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL (TOPIC); CONFUSION; CYTOKINE PRODUCTION; CYTOKINE RELEASE SYNDROME; CYTOPENIA; DIARRHEA; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEVER; FOLLICULAR LYMPHOMA; GENETIC ENGINEERING; HERPES ZOSTER; HUMAN; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; HYPOTENSION; HYPOXEMIA; HYPOXIA; INFLAMMATION; INTRACELLULAR SIGNALING; LARGE CELL LYMPHOMA; LIGHT CHAIN; LYMPHOCYTOPENIA; MACROPHAGE ACTIVATION; MYALGIA; NEUTROPENIA; PNEUMONIA; REGULATORY T LYMPHOCYTE; RESPIRATORY FAILURE; REVIEW; SEIZURE; SPLENIC MARGINAL ZONE LYMPHOMA; SUICIDE GENE THERAPY; T LYMPHOCYTE; TRANSIENT EXPRESSION; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANTIGENS, CD19; GENETIC THERAPY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOMA, B-CELL; PATIENT SELECTION; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT PROTEINS; RECURRENCE; RISK FACTORS; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 84890205877     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2014.860442     Document Type: Review

References (75)

1. Flowers CR, Armitage JO. A decade of progress in lymphoma: advances and continuing challenges. Clin Lymphoma Myeloma Leuk 2010;10(6):414-23
2. Gribben JG, O'Brien S. Update on therapy of chronic lymphocytic leukemia. J Clin Oncol 2011;29(5):544-50
3. Tedder TF. CD19: a promising B cell target for rheumatoid arthritis. Nat Rev Rheumatol 2009;5(10):572-7
4. Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol 2012;1(1):36
5. Carter RH, Fearon DT. CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science 1992;256(5053):105-7
6. Haas K, Tedder TF. Role of the CD19 and CD21/35 receptor complex in innate immunity, host defense and autoimmunity. Adv Exp Med Biol 2005;560:125-39
7. Ishikawa H, Tsuyama N, Mahmoud MS, et al. CD19 expression and growth inhibition of tumours in human multiple myeloma. Leuk Lymphoma 2002;43(3):613-16
8. Del Nagro CJ, Otero DC, Anzelon AN, et al. CD19 function in central and peripheral B-cell development. Immunol Res 2005;31(2):119-31
9. Van Zelm MC, Reisli I, van der Burg M, et al. An antibody-deficiency syndrome due to mutations in the CD19 gene. N Engl J Med 2006;354(18):1901-12
10. Patel VL, Mahévas M, Lee SY, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood 2012;119(25):5989-95
11. Grossbard ML, Multani PS, Freedman AS, et al. A phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma A phase II study of adjuvant therapy with anti-b4-blocked ricin after autologous Bone M. Clin Cancer Res 1999;5:2392-8
12. Younes A, Kim S, Romaguera J, et al. Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. J Clin Oncol 2012;30(22):2776-82
13. Topp MS, Gokbuget N, Zugmaier G, et al. Long-term follow-up of hematologic relapse-free survival in a Phase II study of blinatumumab in patients with MRD in B-lineage ALL. Blood 2012;120(26):5185-7
14. Greenberg PD, Reusser P, Goodrich J, Riddell SR. Development of a Treatment Regimen for Human Cytomegalovirus (CMV) infection in bone marrow transplantation recipients by adoptive transfer of donor-derived CMV-specific T cell clones expanded in vitro. Ann NY Acad Sci 1991;636:184-95
15. Rosenberg SA. Cell transfer immunotherapy for metastatic solid cancer - what clinicians need to know. Nat Rev Clin Oncol 2011;8:577-85
16. Rapoport AP, Stadtmauer EA, Aqui N, et al. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med 2005;11(11):1230-7
17. Hunder NN, Wallen H, Cao J, et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 2008;358(25):2698-703
18. Porter D, Roth M, McGarigle C, et al. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 1994;330:100-6
19. Gill S, Porter DL. Reduced-intensity hematopoietic stem cell transplants for malignancies: harnessing the graft-versus-tumor effect. Annu Rev Med 2013;64:101-17
20. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012;12(4):298-306
21. Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA 1989;86(24):10024-8
22. Kalos M, June CH. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity 2013;39(1):49-60
23. Savoldo B, Ramos CA, Liu E, et al. Brief report CD28 costimulation improves expansion and persistence of chimeric antigen receptor - modified T cells in lymphoma patients. J Clin Invest 2011;121(5):1822-6
24. Jensen MC, Popplewell L, Cooper LJ, et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19- specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant 2010;16(9):1245-56
25. Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011;365(8):725-33
26. Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010;116(20):4099-102
27. Brentjens RJ, Riviere I, Park JH, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011;4817-28
28. Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol 2003;3(8):609-20
29. Imai C, Mihara K, Andreansky M, et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 2004;18(4):676-84
30. Finney HM, Akbar AN, Alastair DG. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134 and CD137 in series with signals from the TCRz chain. J Immunol 2004;172:104-13
31. Maher J, Brentjens RJ, Gunset G, et al. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat Biotechnol 2002;20(1):70-5
32. Brentjens RJ, Santos E, Nikhamin Y, et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res 2007;13(18 Pt 1):5426-35
33. Milone MC, Fish JD, Carpenito C, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 2009;17(8):1453-64
34. Pule MA, Straathof KC, Dotti G, et al. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther 2005;12(5):933-41
35. Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010;18(4):843-51
36. Till BG, Jensen MC, Wang J, et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 2012;119(17):3940-50
37. Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol 2002;2(4):251-62
38. Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011;3(95):95ra73-3
39. Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013;5(177):177ra38
40. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368(16):1509-18
41. Cruz CRY, Micklethwaite KP, Savoldo B, et al. Infusion of donorderived CD19-redirected-virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a Phase I study. Blood 2013; prepublish
42. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigenreceptor- transduced T cells. Blood 2012;119:2709-20
43. Berger C, Jensen MC, Lansdorp PM, et al. Adoptive transfer of effector CD8 + T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 2008;118:294-305
44. Hinrichs CS, Borman ZA, Cassard L, et al. Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc Natl Acad Sci USA 2009;106(41):17469-74
45. Muranski P, Boni A, Antony PA, et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008;112(2):362-73
46. Gattinoni L, Lugli E, Ji Y, et al. A human memory T cell subset with stem cell-like properties. Nat Med 2011;17(10):1290-7
47. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012;12(4):269-81
48. Pegram HJ, Lee JC, Hayman EG, et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 2012;119(18):4133-41
49. Till BG, Jensen MC, Wang J, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 2008;112(6):2261-71
50. Kowolik CM, Topp MS, Gonzalez S, et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 2006;66(22):10995-1004
51. Heslop HE, Slobod KS, Pule MA, et al. Long-term outcome of EBV-specific Tcell infusions to prevent or treat EBVrelated lymphoproliferative disease in transplant recipients. Blood 2010;115(5):925-35
52. Scholler J, Brady TL, Binder-Scholl G, et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med 2012;4(132):132ra53
53. June CH. Science in medicine adoptive T cell therapy for cancer in the clinic. J Clin Invest 2007;117(6):1466-76
54. Zhao Y, Moon E, Carpenito C, et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res 2010;70(22):9053-61
55. Terakura S, Yamamoto TN, Gardner RA, et al. Generation of CD19- chimeric antigen receptor modified CD8 + T cells derived from virus-specific central memory T cells. Blood 2012;119(1):72-82
56. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008;14(11):1264-70
57. Klebanoff CA, Khong HT, Antony PA, et al. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol 2005;26(2):111-17
58. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298(5594):850-4
59. Laport GG, Levine BL, Stadtmauer EA, et al. Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. Blood 2003;102(6):2004-13
60. Muranski P, Boni A, Wrzesinski C, et al. Increased intensity lymphodepletion and adoptive immunotherapy - how far can we go? Nat Clin Pract Oncol 2006; 3(12):668-81
61. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005;105(8): 3051-7
62. Grupp SA, Prak EL, Boyer J, et al. Adoptive transfer of autologous T cells improves T-cell repertoire diversity and long-term B-cell function in pediatric patients with neuroblastoma. Clin Cancer Res 2012;18(24):6732-41
63. Rapoport AP, Stadtmauer EA, Aqui N, et al. Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of Costimulated autologous T cells. Clin Cancer Res 2009;15(13):4499-507
64. Weber JS, Yang JC, Topalian SL, et al. The use of interleukin-2 and lymphokine-activated killer cells for the treatment of patients with non- Hodgkin's lymphoma. J Clin Oncol 1992;10(1):33-40
65. Zhang H, Chua KS, Guimond M, et al. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat Med 2005;11(11):1238-43
66. Teachey DT, Rheingold SR, Maude SL, et al. Cytokine release syndrome after blinatumumab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 2013;121(26):5154-7
67. Lazarus HM, Richards SM, Chopra R, et al. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993. Blood 2006;108(2):465-72
68. Kochenderfer JN, Yu Z, Frasheri D, et al. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood 2010;116(19):3875-86
69. Leen AM, Myers GD, Sili U, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006;12(10):1160-6
70. Marin V, Kakuda H, Dander E, et al. Enhancement of the anti-leukemic activity of cytokine induced killer cells with an anti-CD19 chimeric receptor delivering a 4-1BB-zeta activating signal. Exp Hematol 2007;35(9):1388-97
71. Haso W, Lee DW, Shah NN, et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood 2013;121(7):1165-74
72. Hudecek M, Schmitt TM, Baskar S, et al. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood 2010;116(22):4532-41
73. Vera J, Savoldo B, Vigouroux S, et al. T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocytederived malignant cells. Blood 2006;108(12):3890-7
74. Stephan MT, Ponomarev V, Brentjens RJ, et al. T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med 2007;13(12):1440-9
75. Di Stasi A, Tey S-K, Dotti G, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 2011;365(18):1673-83